Company profile for ImmuneSensor Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of disease. Leveraging the incredible versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address both cancers and a...
ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of disease. Leveraging the incredible versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address both cancers and autoimmune diseases. Our growing pipeline includes STING agonists, designed to elicit anticancer immunity, as well as cGAS antagonists, which work to suppress autoimmunity.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2110 Research Row Suite 610 Dallas, TX 75235
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/11/20/2984389/0/en/ImmuneSensor-Therapeutics-Receives-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-from-the-U-S-FDA-for-cGAS-Inhibitor-Drug-Candidate-IMSB301-for-the-Treatment-of-Aicardi-Gouti.html

GLOBENEWSWIRE
20 Nov 2024

https://www.globenewswire.com/en/news-release/2024/10/08/2959610/0/en/ImmuneSensor-Therapeutics-Initiates-Dosing-in-Phase-1-Clinical-Trial-of-Lead-cGAS-Inhibitor-Drug-Candidate-IMSB301.html

GLOBENEWSWIRE
08 Oct 2024

https://www.globenewswire.com/news-release/2024/09/17/2947387/0/en/ImmuneSensor-Therapeutics-Granted-New-U-S-Patent-for-its-Oral-cGAS-Inhibitors.html

GLOBENEWSWIRE
17 Sep 2024

https://www.globenewswire.com/news-release/2024/09/16/2947008/0/en/ImmuneSensor-Therapeutics-to-Participate-in-the-UBS-2024-Virtual-Biotechnology-Private-Company-Symposium.html

GLOBENEWSWIRE
16 Sep 2024

https://www.globenewswire.com/news-release/2024/08/19/2932072/0/en/ImmuneSensor-Therapeutics-Receives-Clearance-from-Australian-Regulators-to-Initiate-a-First-in-Human-Phase-1-Clinical-Trial-of-cGAS-inhibitor-Drug-Candidate-IMSB301.html

GLOBENEWSWIRE
19 Aug 2024

https://www.globenewswire.com/news-release/2024/05/01/2873194/0/en/ImmuneSensor-Therapeutics-Appoints-Veteran-Biopharma-Executive-Thomas-W-Dubensky-Jr-Ph-D-as-Chief-Executive-Officer.html

GLOBENEWSWIRE
01 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty